AKT1 and B-cell chronic lymphocytic leukemia: Based on the hypothesis that bendamustine and AKT inhibition affect cancer growth via different mechanisms, synergism between bendamustine and MK2206 has recently been tested and demonstrated in patient‐derived CLL cells (Ding et al, 2013).